A detailed history of Royal Bank Of Canada transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Royal Bank Of Canada holds 73,146 shares of ABUS stock, worth $228,215. This represents 0.0% of its overall portfolio holdings.

Number of Shares
73,146
Previous 107,219 31.78%
Holding current value
$228,215
Previous $268,000 29.85%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$2.26 - $2.92 $77,004 - $99,493
-34,073 Reduced 31.78%
73,146 $188,000
Q4 2023

Feb 14, 2024

SELL
$1.69 - $2.54 $15,133 - $22,745
-8,955 Reduced 7.71%
107,219 $268,000
Q3 2023

Nov 14, 2023

BUY
$1.9 - $2.27 $202,177 - $241,548
106,409 Added 1089.7%
116,174 $235,000
Q2 2023

Aug 14, 2023

SELL
$2.24 - $3.06 $183,711 - $250,962
-82,014 Reduced 89.36%
9,765 $22,000
Q1 2023

May 15, 2023

SELL
$2.23 - $3.1 $4,602 - $6,398
-2,064 Reduced 2.2%
91,779 $278,000
Q4 2022

Feb 14, 2023

BUY
$1.91 - $2.85 $2,486 - $3,710
1,302 Added 1.41%
93,843 $218,000
Q3 2022

Nov 14, 2022

SELL
$1.88 - $2.88 $57,200 - $87,626
-30,426 Reduced 24.74%
92,541 $177,000
Q2 2022

Aug 15, 2022

SELL
$1.98 - $3.17 $14,271 - $22,849
-7,208 Reduced 5.54%
122,967 $334,000
Q1 2022

May 16, 2022

SELL
$2.42 - $3.98 $43,354 - $71,301
-17,915 Reduced 12.1%
130,175 $388,000
Q4 2021

Feb 14, 2022

BUY
$3.11 - $4.61 $11,360 - $16,840
3,653 Added 2.53%
148,090 $576,000
Q3 2021

Nov 15, 2021

BUY
$2.65 - $4.62 $226,686 - $395,204
85,542 Added 145.24%
144,437 $620,000
Q2 2021

Aug 16, 2021

BUY
$2.5 - $3.51 $147,237 - $206,721
58,895 New
58,895 $179,000

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $468M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.